Embozene™ and Tandem™ are now sold by Varian.
Tumour Management > Sized For Economic Success
Embolisation therapy for liver cancer: Reliable and consistent preparation using chemotherapeutic agents
Doxorubicin (DX) is cytotoxic, embryotoxic, carcinogenic, teratogenic, and mutagenic
- These potentially severe side effects make DX exposure a significant health and safety threat to laboratory staff and other personnel who may be subjected to accidental exposure.
(Working with Doxorubicin - VCU Office of Environmental Health & Safety)
Use of Pre-filled syringe vs Vial
Drug loading capacity: Load more with less
Dose of chemotherapeutic agent used in an embolisation procedure might vary from 50mg to 150mg per patient
TANDEM™ loading capacity
TANDEM can load 50mg/ml or the 150mg maximum dose by patient in a single 3ml syringe instead of 2ml container.
- 1 single syringe to deliver 150 mg maximum dose per patient
- Preparation & procedural standardisation
Cost-effectiveness (CE) of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolisation for hepatocellular carcinoma.
Results from a meta-analysis of the pertinent literature were used to construct a CE Markov simulation model which followed a hypothetical cohort of HCC patients who underwent DEB-TACE or cTACE, covering the entire post-TACE lifespan until death. Costs were assessed from the health-care provider perspective.
Dig Liver Dis. 2016 Jul;48(7):798-805.
Direct incremental costs of DEB-TACE are not particularly high in comparison to cTACE:
DEB-TACE was found more cost-effective than cTACE when a minimum willingness-to-pay of about 2.000–3500€/QALY was accepted, mainly depending on shorter in-hospital stay and better quality of life.
- DEB-TACE and cTACE have the same safety profile
- DEB-TACE is associated with a shorter in-hospital stay, likely due to the reduced risk of post-TACE syndrome
- DEB-TACE offers a longer quality-adjusted life-expectancy in comparison to cTACE. In the analysis of RCTs, patients treated with cTACE had a mean quality-adjusted life-expectancy of 3.3 ± 0.5 QALYs, whereas in patients submitted to DEB-TACE had a mean of 4.0 ± 0.6 QALYs
A new treatment is considered more cost-effective than the competing one when the ICER remains below of the WTP threshold of US$50,000 (around €44,000) .
- DEB-TACE resulted cost-effective at a monetary value significantly lower than such threshold.